AB Science announced that abstracts reporting the use of Kinavet (masitinib) in the treatment of amyotrophic lateral sclerosis (ALS) were selected for oral presentation at six international meetings in 2017. The abstracts include both preclinical and clinical data. The meetings include: XXIII World Congress of Neurology (WCN 2017) in Kyoto, Japan,…
News
Measuring changes in how humans find their way could enable earlier diagnosis of dementia in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) or Alzheimer’s disease, a new review study suggests. The research, “The Aging Navigational System,” appeared…
Amyotrophic lateral sclerosis (ALS) patients without any type of eye disease have thinner retinal layers, a new study shows. The research, titled “Retinal thinning in amyotrophic lateral sclerosis patients without ophthalmic disease” was published in the journal PLOS…
Routinely measuring neurofilaments in the blood and spinal fluid of people with amyotrophic lateral sclerosis (ALS) can help identify patients with early symptoms, concludes a recent study. Researchers led by Dr. Emily Feneberg of England’s University of Oxford presented the study, “Multicenter evaluation of neurofilaments in early symptom onset amyotrophic…
The company Verge Genomics, which uses genomic data for neuroscience therapeutics, announced that it will join specialized departments at four top universities to boost research in amyotrophic lateral sclerosis (ALS). The innovative industry-academic collaboration will combine machine learning with genomic, genetic, biological, and phenotypical data to accelerate the translation…
Research into the development of new therapies to treat several traumatic, inflammatory, and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) received an important financial boost with the announcement by Disarm Therapeutics that it will receive $30 million in financing to develop treatments for axonal degeneration. Disarm was founded in 2016 as a…
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Revalesio’s investigational drug RNS60 to treat amyotrophic lateral sclerosis (ALS). The status gives incentives for companies to develop new therapies targeting rare and serious diseases, providing marketing exclusivity for…
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS), Amylyx Pharmaceuticals, the drug developer, announced in a press release. Orphan drug status aims to encourage therapies for rare and serious diseases through incentives such as seven years of market…
A mechanism that cells normally use to keep them healthy was found to have a dual role in amyotrophic lateral sclerosis (ALS). While the process, called autophagy, delays disease progression in early stages, it contributes to ALS’s deadly spread through the spinal cord in later stages. This study, “…
News
In New Book, ALS Researcher Niels Birbaumer Explores Brain’s Limitless Capacity to Remodel Itself
Neuroscientist and professor Niels Birbaumer, a senior research fellow at Switzerland’s Wyss Center in Geneva, has written a new book investigating the brain’s seemingly limitless capacity to reshape itself and overcome disease. Birbaumer has conducted research with amyotrophic lateral sclerosis (ALS) patients who, because of their progressive motor neuron disease, have…
Recent Posts
- ALS Network, ALS United calling for ‘bold’ research proposals for funding
- Study finds common medications that could be repurposed to treat ALS
- New eye imaging approach may help distinguish ALS from Alzheimer’s
- After 15 years as an ALS caregiver, I’m still learning from others
- Early PrimeC use slows ALS progression, reduces complication risk